BonesLabsBlog
Back to all posts
Uncategorized

GHRH

GHRH: The Hypothalamic Master Regulator of Growth Hormone Secretion

Research summary. Growth Hormone-Releasing Hormone (GHRH) is the principal hypothalamic peptide that drives growth hormone (GH) synthesis and pulsatile release from anterior pituitary somatotrophs. It was characterised in 1982 by the laboratory of Roger Guillemin from human pancreatic-tumour ectopic GHRH and is the foundation of the modern understanding of the GH-IGF-1 axis. Native human GHRH is a 44-amino-acid peptide (with a 40-residue alternative form), of which the first 29 N-terminal residues are sufficient for full receptor activity. Most GHRH analogues used in research and clinical contexts are based on this 1–29 fragment.

Molecular profile

  • Native length: 44 amino acids (predominant form; 40-residue form also occurs naturally)
  • Active fragment: N-terminal 1–29 residues
  • Molecular weight (full-length 44-mer): ~5039.7 g/mol
  • PubChem CID: 44134750
  • CAS Number: 9034-39-3
  • Synonyms: Somatocrinin, somatoliberin, growth hormone-releasing factor (GRF)

Mechanism of action

GHRH binds the GHRH receptor (GHRHR), a class B G-protein-coupled receptor expressed on anterior pituitary somatotrophs. Receptor activation produces:

  • cAMP-mediated GH gene transcription through Gαs/PKA/CREB signalling
  • Acute GH release from preformed secretory vesicles
  • Stimulation of somatotroph proliferation with chronic exposure

The native peptide is rapidly cleaved by dipeptidyl peptidase-IV (DPP-IV) at the N-terminus, giving it a plasma half-life of approximately 7–10 minutes. This short half-life is biologically appropriate for native pulsatile signalling but is a major limitation for pharmacological use, motivating extensive analogue engineering.

GHRH analogues in research and therapeutic use

Several engineered GHRH variants are widely used:

  • Sermorelin (GHRH 1–29, no modifications): Approved for paediatric growth hormone deficiency in the past; relatively short half-life (~10–20 min)
  • Tesamorelin (Egrifta): GHRH 1–44 with a trans-3-hexenoyl group on the N-terminus to resist DPP-IV cleavage; FDA-approved for HIV-associated lipodystrophy
  • Mod GRF 1–29 (CJC-1295 No DAC): GHRH 1–29 with four amino-acid substitutions (D-Ala, Gln, Ala, Leu) for stabilisation; ~30 minute half-life
  • CJC-1295 DAC: Mod GRF 1–29 with an additional maleimide linker for irreversible albumin binding; ~6–8 day half-life

These analogues differ in their pulsatility-preservation profile: shorter-acting variants better preserve natural pulsatile GH release, while longer-acting variants produce more sustained elevations in mean GH and IGF-1.

Preclinical and clinical research highlights

Sleep regulation. A substantial proportion of total daily GH secretion occurs during slow-wave (NREM) sleep. GHRH has been associated with promotion of NREM sleep, and suppression of GHRH activity has been linked to NREM disruption. This has supported research interest in the GH-axis as a contributor to cognitive dysfunction in sleep disorders such as obstructive sleep apnoea.

Body composition. GHRH stimulation of GH release supports lean mass accretion and reduces visceral adiposity, with downstream effects mediated largely through hepatic IGF-1. These effects underlie the use of tesamorelin in HIV-associated visceral adiposity.

Aging and sarcopenia. Plasma GH and IGF-1 decline progressively with age, and studies in older adults have reported that GHRH analogue administration can partially restore these parameters with associated improvements in muscle strength and bioenergetics.

Stress and inflammation. GHRH secretion is suppressed under stress through neuropeptide Y-mediated mechanisms. Chronic stress-induced GHRH suppression has been implicated in stress-associated growth restriction in pediatric contexts.

Pain and fibromyalgia. Rat studies have reported analgesic activity for GHRH in inflammatory pain models, with pain reduction reported in fibromyalgia-relevant contexts in some clinical investigations.

Benign prostatic hyperplasia (BPH). A counter-intuitive line of research has examined GHRH antagonists (notably the MZ-J-7 series developed by Andrew Schally's group) for BPH. Antagonist administration in mouse models has been reported to reduce prostatic inflammation and hyperplasia.

Why GHRH biology matters

GHRH sits at the apex of the GH-IGF-1 axis. Engineering the GHRH receptor surface — through stabilised analogues, biased agonists, or antagonists — has yielded an unusually rich set of clinical-stage molecules: sermorelin (approved historically), tesamorelin (FDA-approved), and a portfolio of antagonists in oncology research. The basic-science significance of GHRH for understanding pulsatile endocrine signalling has been equally substantial, with GHRH and somatostatin together constituting the canonical example of opposing hypothalamic neuropeptide regulation of an anterior pituitary axis.

Current research status

Native GHRH itself is rarely used directly in clinical research because of its short half-life; engineered analogues dominate practical applications. Tesamorelin is the only GHRH analogue currently with broad U.S. FDA approval, for HIV-associated lipodystrophy. Other analogues are used as research peptides and in selected clinical investigation contexts. GHRH and its analogues are listed by the World Anti-Doping Agency as prohibited substances under category S2.

Key takeaways for researchers

  • GHRH is the hypothalamic master regulator of pituitary GH secretion, acting through GHRHR on somatotroph cells.
  • Native GHRH is rapidly cleaved by DPP-IV; most research and therapeutic use involves engineered analogues with extended half-life.
  • Major analogues include sermorelin, tesamorelin (FDA-approved), Mod GRF 1–29, and CJC-1295 DAC.
  • Reported activity spans GH/IGF-1 axis biology, sleep regulation, body composition, age-related decline, and pain modulation.
  • GHRH and its analogues are on the WADA Prohibited List.

References

  1. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585–587.

This article is provided for educational and research purposes only. GHRH and its analogues are research peptides (with the exception of FDA-approved tesamorelin). They are not generally intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition outside of approved indications and supervised clinical use. GHRH and its analogues are listed by the World Anti-Doping Agency as prohibited substances. All work involving these peptides should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.

GHRH | BonesLabs